Related Experiment Videos
Abstract:
Obesity is rapidly becoming a worldwide epidemic, with significant consequences in terms of clinical burden and economic costs in treating its complications, so effective new approaches are urgently needed. Development of new drugs in this therapeutic area requires a detailed understanding of the physiology underlying body weight regulation. Recently several significant advances have been made in this area, including the identification of the appetite regulating hormone, leptin, and a detailed understanding of its targets in the central nervous system (CNS), such as neuropeptide Y (NPY) and the melanocortin-4 receptor. The observation that some humans with severe childhood-onset obesity have defects in these regulatory systems has confirmed their relevance in humans as well as in animal models, and the search is now on to produce drugs which act on these and other CNS targets such as glucagon-like peptide I and the orexins to help reduce body weight. Other recently identified targets outside the central nervous system include agents acting to inhibit digestive enzymes, specifically pancreatic lipase in the form of orlistat (which has recently been licensed for obesity treatment), and looking to the future, the possibility of altering energy expenditure by modulating the newly identified uncoupling proteins is being considered. It should be remembered however, that pharmacotherapy for obesity is unlikely to provide a 'magic bullet', and that diet and lifestyle changes are likely to remain the cornerstone of treatment for the foreseeable future.
Insights
Obesity is a growing global epidemic requiring new treatments. Research focuses on appetite hormones like leptin and targets in the central nervous system (CNS) for effective weight management drugs.
Area of Science:
- Endocrinology
- Neuroscience
- Pharmacology
Background:
- Obesity is a worldwide epidemic with substantial clinical and economic burdens.
- Effective new therapeutic approaches are urgently needed.
- Understanding body weight regulation physiology is key for drug development.
Purpose of the Study:
- To review recent advances in understanding body weight regulation.
- To identify current and future drug targets for obesity pharmacotherapy.
- To discuss the role of central and peripheral targets in weight management.
Main Methods:
- Review of recent scientific literature on obesity and weight regulation.
- Identification of key hormones, receptors, and pathways involved in appetite control.
- Analysis of existing and emerging pharmacological targets for obesity treatment.
Main Results:
- Significant advances include the identification of leptin and its CNS targets (NPY, melanocortin-4 receptor).
- Defects in these systems are linked to severe obesity, confirming their relevance.
- Emerging targets include glucagon-like peptide I, orexins, pancreatic lipase inhibitors (orlistat), and uncoupling proteins.
Conclusions:
- Pharmacotherapy for obesity is advancing with new CNS and peripheral targets.
- Orlistat is licensed, and other agents are under development.
- Diet and lifestyle changes remain fundamental to obesity treatment.